CBER Biologics Effectiveness and Safety (BEST) I Recompete
Type: Forecast
Overview
Description
BEST 1 recompete on schedule to be awarded by July 2025. The BEST Contractor's purpose is to conduct biologic product safety and effectiveness studies for products such as vaccines, blood, tissue and advanced therapeutic products regulated by CBER. The Contractor shall provide resources and support to establish a Coordinating Center and an appropriate data source(s) or partner(s) to conduct active biologic product safety and effectiveness studies by CBER using a distributed data model using a large data source.
Est. Value
Min: $50,000,000
Max: $100,000,000
Max: $100,000,000
Est. Award Date
9/1/25
Source Est. Solicitation Date
1/1/25
Set Aside
Full and Open
Forecast Type
New
Forecast Source
Health and Human Services
Food and Drug Administration is forecasted to issue a new procurement for CBER Biologics Effectiveness and Safety (BEST) I Recompete around 9/1/25 worth up to $100,000,000.
Agency
Source Level 1 Agency
Health and Human Services
Source Level 2 Agency
Food and Drug Administration
Contacts
Potential Bidders and Partners
Similar Active Opportunities
Additional Detail
Date Published
9/18/24